FDA takes step to improve generic drug competition

In the last day or so, we’ve talked about how the amount we paid for prescription drugs last year slowed down dramatically compared to 2014.

You know we’d all be paying a whole lot more if it wasn’t for generics, which amounts to as much as 85% of what we take.

The Food and Drug Administration recently said it’s going to prioritize any generic drug application when there’s currently just one manufacturer.

Here’s why:

At the University of Utah Healthcare, pharmacist Erin Fox said in about a year, the heart medication Isuprel went from $50 a dose to $1800 after Valeant purchased the drug.

She said they had always stocked on crash carts.

“Basically, it’s the kind of [drug] you might see on TV, code blue, cardiac arrest, everyone is rushing around,” she said. It’s the kind of medication that can save a life, she said.

But at $1800 a dose, it got pulled off the carts, only to be used in extreme emergencies.

This is what happens when a company has a lock on a given drug.
 
Sign Up for Our Email Newsletter

RECENT NEWS

War on Vaping Threatens Public Health

War on Vaping Threatens Public Health

Will the government hamstring what is potentially the most important public health innovation of the 21st century?...  Read more

PBMs Are Hogging Our Drug Discounts

PBMs Are Hogging Our Drug Discounts

PBMs are knowingly profiting off the backs of American patients, pharmacists, and innovators....  Read more

Advancing 21st Century Pain Management Conference (August 17, 2018)

Advancing 21st Century Pain Management Conference (August 17, 2018)

CMPI conference: Advancing 21st Century Pain Management Keynote Speaker: FDA Commissioner Scott Gottlieb...  Read more

DRUGWONKS BLOG